Molbio Diagnostics announces investment of $85 million from Global investment company Temasek

 Goa-based Molbio Diagnostics has announced that Temasek has invested $85 million in the company. 
Molbio is known for its game-changing Truenat® technology – a point-of-care, portable, battery-operated Real-Time PCR platform. The platform can test for over 40 diseases in addition to TB, including COVID-19, Hepatitis, HIV, HPV, and vector-borne diseases like Dengue, Chikungunya and Malaria.

Mr Sriram Natarajan, Director and CEO, Molbio Diagnostics, said, “The strategic partnership with Temasek will strengthen our ability to provide sustainable choices to address global healthcare challenges.”Rohit Mantri, Director at Motilal Oswal Alternates said, “Molbio is playing a very important role in ramping up of the testing infrastructure in India. Now, as the company goes global, we continue to remain extremely excited and welcome Temasek as a new partner in Molbio's growth journey.” Allegro Capital acted as exclusive advisors for this transaction.